KR101992925B1 - 유전자 발현 조절을 위한 올리고뉴클레오타이드 및 그 용도 - Google Patents

유전자 발현 조절을 위한 올리고뉴클레오타이드 및 그 용도 Download PDF

Info

Publication number
KR101992925B1
KR101992925B1 KR1020147026837A KR20147026837A KR101992925B1 KR 101992925 B1 KR101992925 B1 KR 101992925B1 KR 1020147026837 A KR1020147026837 A KR 1020147026837A KR 20147026837 A KR20147026837 A KR 20147026837A KR 101992925 B1 KR101992925 B1 KR 101992925B1
Authority
KR
South Korea
Prior art keywords
oligonucleotide
seq
oligonucleotides
gene
pna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147026837A
Other languages
English (en)
Korean (ko)
Other versions
KR20140130514A (ko
Inventor
로베르토 토넬리
레오나르도 벤투렐리
안드레아 토르토리
루카 몬테무로
Original Assignee
바이오제네라 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오제네라 에스.피.에이. filed Critical 바이오제네라 에스.피.에이.
Publication of KR20140130514A publication Critical patent/KR20140130514A/ko
Application granted granted Critical
Publication of KR101992925B1 publication Critical patent/KR101992925B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
KR1020147026837A 2012-02-24 2013-02-21 유전자 발현 조절을 위한 올리고뉴클레오타이드 및 그 용도 Active KR101992925B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000275A ITMI20120275A1 (it) 2012-02-24 2012-02-24 Oligonucleotidi per la modulazione dell'espressione genica e loro usi
ITMI2012A000275 2012-02-24
PCT/IB2013/051410 WO2013124807A2 (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and uses thereof

Publications (2)

Publication Number Publication Date
KR20140130514A KR20140130514A (ko) 2014-11-10
KR101992925B1 true KR101992925B1 (ko) 2019-06-25

Family

ID=45999941

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147026837A Active KR101992925B1 (ko) 2012-02-24 2013-02-21 유전자 발현 조절을 위한 올리고뉴클레오타이드 및 그 용도

Country Status (28)

Country Link
US (2) US10023867B2 (cg-RX-API-DMAC7.html)
EP (1) EP2817407B1 (cg-RX-API-DMAC7.html)
JP (2) JP6333739B2 (cg-RX-API-DMAC7.html)
KR (1) KR101992925B1 (cg-RX-API-DMAC7.html)
CN (2) CN115216475A (cg-RX-API-DMAC7.html)
AR (1) AR090129A1 (cg-RX-API-DMAC7.html)
AU (2) AU2013223694B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014020885B1 (cg-RX-API-DMAC7.html)
CA (1) CA2864060C (cg-RX-API-DMAC7.html)
CY (1) CY1120084T1 (cg-RX-API-DMAC7.html)
DK (1) DK2817407T3 (cg-RX-API-DMAC7.html)
ES (1) ES2651147T3 (cg-RX-API-DMAC7.html)
HK (1) HK1201878A1 (cg-RX-API-DMAC7.html)
HU (1) HUE034846T2 (cg-RX-API-DMAC7.html)
IN (1) IN2014MN01493A (cg-RX-API-DMAC7.html)
IT (1) ITMI20120275A1 (cg-RX-API-DMAC7.html)
LT (1) LT2817407T (cg-RX-API-DMAC7.html)
MA (1) MA35935B1 (cg-RX-API-DMAC7.html)
NO (1) NO2817407T3 (cg-RX-API-DMAC7.html)
PL (1) PL2817407T3 (cg-RX-API-DMAC7.html)
PT (1) PT2817407T (cg-RX-API-DMAC7.html)
RS (1) RS56631B1 (cg-RX-API-DMAC7.html)
RU (1) RU2648140C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201404852WA (cg-RX-API-DMAC7.html)
SI (1) SI2817407T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800042T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000327A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013124807A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi
CA2873794A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating smn gene family expression
US20150152410A1 (en) 2012-05-16 2015-06-04 Rana Therapeutics, Inc. Compositions and methods for modulating mecp2 expression
EP2850185A4 (en) 2012-05-16 2015-12-30 Rana Therapeutics Inc COMPOSITIONS AND METHOD FOR MODULATING UTRN GENE EXPRESSION
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
AU2013262700A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating hemoglobin gene family expression
WO2013173598A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating atp2a2 expression
US11033571B2 (en) 2016-12-13 2021-06-15 Am Sciences Inc Pharmaceutical composition for preventing or treating hepatitis B
WO2023182812A1 (ko) * 2022-03-22 2023-09-28 주식회사 바이오엔 담즙산염 및 양이온성 펩타이드를 포함하는 단백질 전달용 조성물 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019429A4 (en) * 1997-08-20 2001-08-08 Somagenics Inc ANTISENSE THERAPEUTIC PRODUCTS WITH IMPROVED BINDING PROPERTIES AND METHODS OF USE
EP1257665A2 (en) 2000-02-14 2002-11-20 Inc. Cytoclonal Pharmaceutics LIBRARIES OF OPTIMUM SUBSEQUENCE REGIONS OF mRNA AND GENOMIC DNA FOR CONTROL OF GENE EXPRESSION
EP1392366A4 (en) * 2001-04-13 2005-01-19 Population Council Inc CORE RECEPTOR-MEDIATED INTRODUCTION OF A PNA PROTEIN IN CELL CHERRIES
KR20040004629A (ko) 2001-05-17 2004-01-13 에이브이아이 바이오파마 인코포레이티드 ｃ-ｍｙｃ 안티센스 올리고머를 사용한 암치료를 위한조합 접근법
EP1448590A4 (en) * 2002-02-20 2004-12-15 Sirna Therapeutics Inc Inhibition of the myc and myb genes mediated by RNA interference mediated or genes of the corresponding synthetic pathways
ITMI20030860A1 (it) * 2003-04-29 2004-10-30 Univ Bologna Metodo per l'inibizione selettiva del gene n-myc
WO2005045032A2 (en) * 2003-10-20 2005-05-19 Sima Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
JP2008517627A (ja) * 2004-10-25 2008-05-29 ノバルティス アクチエンゲゼルシャフト Ｔｏｒｃポリヌクレオチドおよびポリペプチドならびに使用法
US20090324587A1 (en) * 2005-12-01 2009-12-31 Neal Clifford Goodwin Cancer Therapies and Pharmaceutical Compositions Used Therein
US7625874B2 (en) * 2006-04-11 2009-12-01 The Regents Of The University Of California Compositions and methods for treating diseases associated with T-box and N-Myc
US20080038783A1 (en) * 2006-06-29 2008-02-14 Applera Corporation Compositions and Methods Pertaining to Guanylation of PNA Oligomers
US20090047295A1 (en) 2007-07-12 2009-02-19 Berry David A Methods and Compositions for Reducing Stemness in Oncogenesis
EP2268284A2 (en) * 2008-02-05 2011-01-05 Antisoma Research Limited Use of g-rich oligonucleotides for treating neoplastic diseases
CA2745811C (en) * 2008-12-04 2021-07-13 Joseph Collard Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
CN102058535B (zh) * 2010-12-21 2013-05-01 中国人民解放军总医院 叶酸受体靶向的新型脂质体
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi

Also Published As

Publication number Publication date
US20160040166A1 (en) 2016-02-11
NO2817407T3 (cg-RX-API-DMAC7.html) 2018-02-03
AU2013223694A1 (en) 2014-09-25
KR20140130514A (ko) 2014-11-10
US10023867B2 (en) 2018-07-17
EP2817407A2 (en) 2014-12-31
BR112014020885A2 (pt) 2018-01-09
SG10201606946YA (en) 2016-10-28
CY1120084T1 (el) 2018-12-12
LT2817407T (lt) 2018-01-25
TN2014000327A1 (en) 2015-12-21
US20180282731A1 (en) 2018-10-04
CA2864060A1 (en) 2013-08-29
HUE034846T2 (en) 2018-03-28
DK2817407T3 (en) 2017-12-18
AU2018278972A1 (en) 2019-01-17
PL2817407T3 (pl) 2018-03-30
US10752900B2 (en) 2020-08-25
MA35935B1 (fr) 2014-12-01
JP6333739B2 (ja) 2018-05-30
SMT201800042T1 (it) 2018-03-08
RU2014138198A (ru) 2016-04-10
SI2817407T1 (en) 2018-01-31
ITMI20120275A1 (it) 2013-08-25
SG11201404852WA (en) 2014-10-30
WO2013124807A3 (en) 2013-12-27
AR090129A1 (es) 2014-10-22
BR112014020885B1 (pt) 2020-10-27
WO2013124807A2 (en) 2013-08-29
JP2015513398A (ja) 2015-05-14
ES2651147T3 (es) 2018-01-24
CN104169421A (zh) 2014-11-26
PT2817407T (pt) 2017-12-07
CA2864060C (en) 2020-03-10
HK1201878A1 (en) 2015-09-11
AU2013223694B2 (en) 2019-01-03
CN115216475A (zh) 2022-10-21
RU2648140C2 (ru) 2018-03-22
EP2817407B1 (en) 2017-09-06
JP2018078893A (ja) 2018-05-24
RS56631B1 (sr) 2018-03-30
IN2014MN01493A (cg-RX-API-DMAC7.html) 2015-04-17

Similar Documents

Publication Publication Date Title
KR101992925B1 (ko) 유전자 발현 조절을 위한 올리고뉴클레오타이드 및 그 용도
AU2021203173B2 (en) Multimeric oligonucleotide compounds
Pirollo et al. Antisense therapeutics: from theory to clinical practice
JP2023518970A (ja) 安定性の向上を有する修飾オリゴヌクレオチドの合成
AU2007310982A1 (en) Nicked or gapped nucleic acid molecules and uses thereof
EP3033422A1 (en) Oligonucleotides targeting euchromatin regions of genes
CN117858946A (zh) 作为新型基因沉默技术的非对称短双链体dna及其应用
AU2005270917A1 (en) Gastrin-specific interfering RNA
KR20250107981A (ko) 변형된 올리고뉴클레오타이드
Gewirtz Nucleic Acid-Based, mRNA-Targeted Therapeutics for Hematologic Malignancies
CN111615558A (zh) 用于调节erc1表达的寡核苷酸
AU2014200144A1 (en) Nicked or gapped nucleic acid molecules and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140924

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180221

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20180221

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180701

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190322

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190619

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190620

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220602

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230525

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240618

Start annual number: 6

End annual number: 6